Podcasts about therapeutics

On this episode Gil Bashe welcomes Craig Martin—former acting CEO of Global Genes and founder/CEO of the Orphan Therapeutics Accelerator—about the urgent need to rescue clinically promising drugs for rare and ultra-rare diseases. Craig shares how his nonprofit model uses AI, CDMOs, CROs, and alternative funding to de-risk shelved therapies and transform them into treatments for patients with unmet needs. including context on systemic inequities and the human cost of stalled innovation. He describes a startling trend: when capital dries up or regulations shift, life-saving drug programs get shelved—not because of safety or efficacy issues, but due to dilution in business incentives. Among those left behind are rare disease candidates that patients and families know work, but simply become financially unviable. Martin joins us to unpack a pressing challenge in rare disease therapeutics: promising clinical‑stage drug programs that have been shelved—not for lack of science, but due to shifting capital and incentives. Through his nonprofit model at OTXL, he's pioneering an entirely new approach to rescue these assets and deliver real impact. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

Dan Schmitt, President and CEO of Actuate Therapeutics, is developing a cancer therapy that inhibits GSK3β, a key enzyme that is hijacked in cancer cells to drive tumor growth. Inhibiting this enzyme can impact the cancer cells and stimulate an immune response against the tumor. Actuate selected metastatic pancreatic cancer as their first target due to unmet need and promising data for their lead drug candidate. This could represent a significant advancement in the treatment of metastatic pancreatic cancer, offering a new standard-of-care option.   Dan explains, "So, GSK-3β is a known quantity across a number of inflammatory diseases. It was understood when we first started the company that, particularly in cancer cells, GSK is hijacked in its activity. Basically it's been shown that in normal cells, GSK-3β sits in the cytoplasmic domain and there it's involved in multiple paths, basically in glucose metabolism. But in cancer cells, it translocates into the nuclear compartment, and there it's accumulated at much higher levels and then sits upstream of a pro-oncogenic set of pathways, all mediated by NF-κB. NF-κB is notorious in cancer. It regulates gene expression involved in tumor growth and progression, chemoresistance, and protects tumor cells from death." "So it's been very difficult to target NF-κB directly, but we can target GSK-3β directly, specifically and potently, and therefore downregulate those key oncogenic processes. And that's really where we started the company, that set of activities of this protein. What's been shown since we've been in the clinic is that there is also a resulting upregulation of immune response from the host towards the cancer itself based on this inhibition of GSK-3β as well."  #ActuateTherapeutics #Cancer #PancreaticCancer #MetastaticPancreaticCancer  actuatetherapeutics.com Download the transcript here

Dan Schmitt, President and CEO of Actuate Therapeutics, is developing a cancer therapy that inhibits GSK3β, a key enzyme that is hijacked in cancer cells to drive tumor growth. Inhibiting this enzyme can impact the cancer cells and stimulate an immune response against the tumor. Actuate selected metastatic pancreatic cancer as their first target due to unmet need and promising data for their lead drug candidate. This could represent a significant advancement in the treatment of metastatic pancreatic cancer, offering a new standard-of-care option.   Dan explains, "So, GSK-3β is a known quantity across a number of inflammatory diseases. It was understood when we first started the company that, particularly in cancer cells, GSK is hijacked in its activity. Basically it's been shown that in normal cells, GSK-3β sits in the cytoplasmic domain and there it's involved in multiple paths, basically in glucose metabolism. But in cancer cells, it translocates into the nuclear compartment, and there it's accumulated at much higher levels and then sits upstream of a pro-oncogenic set of pathways, all mediated by NF-κB. NF-κB is notorious in cancer. It regulates gene expression involved in tumor growth and progression, chemoresistance, and protects tumor cells from death." "So it's been very difficult to target NF-κB directly, but we can target GSK-3β directly, specifically and potently, and therefore downregulate those key oncogenic processes. And that's really where we started the company, that set of activities of this protein. What's been shown since we've been in the clinic is that there is also a resulting upregulation of immune response from the host towards the cancer itself based on this inhibition of GSK-3β as well."  #ActuateTherapeutics #Cancer #PancreaticCancer #MetastaticPancreaticCancer  actuatetherapeutics.com Listen to the podcast here

Tech taking it on the chin, as big tech sells off in today's session. The Mag-7 names pulling down the space, and the semi stocks feeling the heat. Plus A biotech bummer. Shares of Viking Therapeutics tanking after the company posted disappointing weight loss drug pill trial data. What it means for the company's next move, and the impact it could have on potential M&A action.Fast Money Disclaimer

This podcast is brought to you by Outcomes Rocket, your exclusive healthcare marketing agency. Learn how to accelerate your growth by going to outcomesrocket.com A key takeaway from this interview is that the most effective path to value-based care starts with building trust, proving outcomes, and aligning your pitch with what payers already prioritize. In this episode, David Ricupero,  Director of Business Development at Affect Therapeutics and Creator of the Out-of-Pocket Course: How to Contract with Payors, explains the full journey of payer contracting, from initial applications to advanced value-based agreements. He covers how to join payer networks, manage closed systems, and prepare key documents and timelines. David explores various value-based care models, illustrating how risk and complexity grow from pay-for-performance to full capitation, and highlights the importance of combining traditional applications with strategic conversations. He also offers practical tips for avoiding “payer purgatory,” identifying payer goals, and asking the right questions during shared savings negotiations. Tune in and learn how to navigate the nuances of payer-provider relationships and set up sustainable, rewarding contracts that truly expand access to care! Resources: Connect with and follow David Ricupero on LinkedIn. Follow Affect Therapeutics on LinkedIn and explore their website.  Register for the “How to Contract with Payors” course here.

Why the Fed could skip a September cut altogether, despite higher inflation data. BTIG makes the case for sticking with Viking Therapeutics despite disappointing weight loss drug trial data. Plus, the laggards our traders says to buy now.  

AI and genetic medicine are converging to transform how we diagnose, treat, and prevent disease. Gene Yeo, Ph.D., unites RNA biology with artificial intelligence to speed the path from genome sequencing to personalized RNA therapeutics. Advances in sequencing have reduced costs dramatically, making interpretation and translation into treatments the real challenge. Using deep learning and large datasets of RNA-binding proteins, Yeo predicts disease vulnerabilities and identifies therapeutic targets, including in neurodegeneration and muscular diseases. Alexis Komor, Ph.D., focuses on DNA, explaining human genetic variation—particularly single-nucleotide variants—and how genome editing technologies like CRISPR can target them. She highlights strategies to correct harmful mutations and explores precise, programmable interventions. Together, their research drives discovery and enables more effective, personalized therapies. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40459]

AI and genetic medicine are converging to transform how we diagnose, treat, and prevent disease. Gene Yeo, Ph.D., unites RNA biology with artificial intelligence to speed the path from genome sequencing to personalized RNA therapeutics. Advances in sequencing have reduced costs dramatically, making interpretation and translation into treatments the real challenge. Using deep learning and large datasets of RNA-binding proteins, Yeo predicts disease vulnerabilities and identifies therapeutic targets, including in neurodegeneration and muscular diseases. Alexis Komor, Ph.D., focuses on DNA, explaining human genetic variation—particularly single-nucleotide variants—and how genome editing technologies like CRISPR can target them. She highlights strategies to correct harmful mutations and explores precise, programmable interventions. Together, their research drives discovery and enables more effective, personalized therapies. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40459]

We love to hear from our listeners. Send us a message. On this week's episode, Milan Kalawadia, CEO, North America, Dr. Reddy's Laboratories, and Arun Swaminathan, Ph.D., CEO, Coya Therapeutics discuss their unique partnership to develop COYA 302, a novel dual-mechanism immunotherapy for the treatment of ALS. The partnership pairs Coya's scientific expertise with Dr. Reddy's manufacturing and commercialization capabilities, putting Coya in a financial position to advance development activities and commercialize COYA 302 upon FDA approval, and providing Dr. Reddy's -- a generics, biosimilars, API, and OTC manufacturer -- with an opportunity to pivot into innovative branded products. Kalawadia and Swaminathan discuss their pathways to the CEO role at each company, respectively, how the partnership came together, ongoing FDA engagement, and what COYA 302 could mean for patients with ALS. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

On August 5, Health Secretary Robert F. Kennedy Jr. announced that the Department of Health and Human Services would terminate almost $500 million in mRNA vaccine development grants and contracts, affecting 22 projects. Biologist and mRNA researcher Jeff Coller joins Host Ira Flatow to talk about what this move means for future mRNA research in the US beyond these immediate projects.Plus, reporter Casey Crownhart joins Ira to discuss the latest in climate news, including flooding in Juneau, Alaska; how Ford is pursuing further electric vehicle manufacturing despite federal roadblocks; and a startup using Earth itself as a giant battery.Guests:Dr. Jeff Coller is the Bloomberg Distinguished Professor of RNA Biology and Therapeutics at Johns Hopkins University.Casey Crownhart is a senior climate reporter for MIT Technology Review in New York, New York.Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

In this episode, Jacob sits down with Joshua Meier, co-founder of Chai Discovery and former Chief AI Officer at Absci, to explore the breakthrough moment happening in AI drug discovery. They discuss how the field has evolved through three distinct waves, with the current generation of companies finally achieving success rates that seemed impossible just years ago.  The conversation covers everything from moving drug discovery out of the lab and into computers, to why AI models think differently than human chemists, to the strategic decisions around open sourcing foundational models while keeping design capabilities proprietary. It's an in-depth look at how AI is fundamentally changing pharmaceutical innovation and what it means for the future of medicine. Check out the full Chai-2 Zero-Shot Antibody report linked here: https://www.biorxiv.org/content/10.1101/2025.07.05.663018v1.full.pdf [0:00] Intro[2:10] The Evolution of AI in Drug Discovery[6:09] Current State and Future of AI in Biotech[11:15] Challenges and Modalities in Therapeutics[15:19] Data Generation and Model Training[23:59] Open Source and Model Development at Chai[28:35] Protein Structure Prediction and Diffusion Models[30:57] Open Source Models and Their Impact[35:41] How Should Chai-2 Be Used?[39:34] The Future of AI in Pharma and Biotech[43:51] Key Milestones and Metrics in AI-Driven Drug Discovery[48:24] Critiques and Hesitation[55:06] Quickfire With your co-hosts: @jacobeffron - Partner at Redpoint, Former PM Flatiron Health @patrickachase - Partner at Redpoint, Former ML Engineer LinkedIn @ericabrescia - Former COO Github, Founder Bitnami (acq'd by VMWare) @jordan_segall - Partner at Redpoint

Rick Geoffrion, Founder and CEO of Cyrano Therapeutics, is developing a drug to restore olfactory function due to post-viral loss of smell and taste. As a result of COVID-19, there has been a significant increase in the number of people affected by long-term smell and taste loss, with no effective pharmaceutical options previously available. Smell loss can also be an early indicator of neurodegenerative conditions, suggesting future applications of the intranasal spray that aims to directly restore function to the olfactory receptor neurons. Rick explains, "Taste and smell have a really strong connection, actually. First of all, they're two out of the five basic senses that we have as human beings. When you lose your sense of smell, people actually perceive that they've lost about 80% of their sense of taste. Now, technically, you're not losing your sense of taste. We actually just give our tongue too much credit. Our tongue is able to detect sweet, sour, salty, bitter, and umami. That's all it detects, and it detects them really in light monotone that are about 80% less intense if you've lost your sense of smell. In addition, if you no longer have your sense of smell, what you've really lost is the ability to detect flavor in food. So, to tell the difference between a peach, a pear, and a strawberry, maybe you'll tell that visually, but to tell it from a flavor perspective, you completely lose that ability.    "There really are no significant therapies to treat the condition right now. Essentially, if you've lost your sense of smell, a physician may recommend that you use smell training, which is essentially the regular smelling of intense essential oils, and they really haven't been shown to significantly treat or cure a chronic smell loss condition. It is thought that if your body is spontaneously recovering, say within those first few months, if you do undergo smell training, you may accelerate that recovery. But other than that, there's certainly no gold standard treatment or no significant treatments available right now, and no pharmaceuticals in the pipeline other than CYR-064, which is being developed by Cyrano." #CyranoTherapeutics #Olfactory #LongCOVID #PostViralLoss #IntranasalSpray #SmellandTaste #LongTermSmellLoss cyranotherapeutics.com Download the transcript here

In this episode of the Xtalks Life Science Podcast, Ayesha speaks with Michael Thurn, PhD, Managing Director & CEO, Neurizon Therapeutics, a company focused on advancing treatments for neurodegenerative diseases, including ALS, with expansion efforts in Alzheimer's, Parkinson's, Huntington's and others. With over 25 years of experience in biotech innovation, entrepreneurship and leadership and broad experience in drug discovery, development, regulation and commercialization, Dr. Thurn shares his vision for advancing next-generation therapies for neurodegenerative diseases. Dr. Thurn has led a variety of FDA lnvestigational New Drug (IND) applications across a range of therapeutic areas, and the evaluation of drugs and vaccines for registration in Australia as a part of the Drug Safety Evaluation Branch (DSEB) of the Therapeutics Goods Administration (TGA). Dr. Thurn co-founded MARP Therapeutics and held roles at companies including Botanix, Mimetica, Spinifex, Cytopia, Xenome and Novogen. Tune in to hear Dr. Thurn discuss Neurizon's strategic pipeline, clinical development efforts, as well as his global experience spanning drug discovery, regulatory affairs and capital markets. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

On July 31, 2025, Eli Lilly and Company announced topline data from the SURPASS‑CVOT trial comparing tirzepatide (Mounjaro) to dulaglutide (Trulicity) in adults with type 2 diabetes and established atherosclerotic cardiovascular disease (ASCVD). According to the data, tirzepatide met the primary non‑inferiority endpoint for 3-point major adverse cardiovascular events (MACE) (hazard ratio [HR], 0.92; 95.3% CI, 0.83 to 1.01), while also showing additional benefits in A1C, weight reduction, renal preservation, and a 16% reduction in all‑cause mortality (HR, 0.84; 95.0% CI, 0.75 to 0.94). In the latest episode of Diabetes Dialogue: Technology, Therapeutics, and Real-World Perspectives, Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and co-director of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, unpacked the top-line results of the SURPASS-CVOT trial. Eli Lilly and Company owns both drugs, which belong to the incretin class, but tirzepatide is a dual GIP/GLP-1 receptor agonist, while dulaglutide is a GLP-1 RA. The trial included over 13,000 adults with type 2 diabetes and either established cardiovascular disease or at high risk. During a median follow-up of 4.5 years, the primary endpoint, which was a composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke, was reduced by 8% in the tirzepatide group relative to dulaglutide. However, the result did not reach statistical superiority due to the confidence interval crossing unity. Isaacs and Bellini also highlighted significantly greater A1c (-1.73% vs -0.9%) and weight loss (12% vs 4.95%) with tirzepatide. Additional prespecified analyses comparing data with the placebo-controlled REWIND trial suggest tirzepatide could offer up to 28% MACE and 39% mortality risk reduction compared to theoretical placebo—findings that hint at broader cardiometabolic benefit. Before concluding, hosts speculated about the potential subgroup analyses of interest for the trial, including heart failure and renal outcomes, as well as a brief discussion around Eli Lilly and Company's intent to submit a regulatory application for a cardiovascular indication before the close of 2025. Relevant disclosures for Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others. References: Eli Lilly and Company. Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease. July 31, 2025. Accessed July 31, 2025. https://investor.lilly.com/news-releases/news-release-details/lillys-mounjaro-tirzepatide-gipglp-1-dual-agonist-demonstrated

In this episode of The Sunday BBQ, Kevin Hornsby is joined by Anthony Tennyson, CEO of Solvonis Therapeutics plc (LSE: SVNS), to discuss the Company's latest progress across its mental health and addiction treatment pipeline. Anthony outlines the £1 million investment from key shareholders to accelerate Solvonis' AI-driven CNS drug discovery programme, as well as the initiation of pivotal translational studies for SVN‑002 — a novel treatment for Alcohol Use Disorder — ahead of a Phase 2b trial in the US. We also explore the company's strategic use of the FDA's 505(b)(2) pathway and why its differentiated pipeline continues to attract attention in the neuropsychiatry space. Disclaimer & Declaration of Interest This podcast may contain paid promotions, including but not limited to sponsorships, endorsements, or affiliate partnerships. The information, investment views, and recommendations provided are for general informational purposes only and should not be construed as a solicitation to buy or sell any financial products related to the companies discussed. Any opinions or comments are made to the best of the knowledge and belief of the commentators; however, no responsibility is accepted for actions based on such opinions or comments. The commentators may or may not hold investments in the companies under discussion. Listeners are encouraged to perform their own research and consult with a licensed professional before making any financial decisions based on the content of this podcast. 

In this episode, Dr. Rachel welcomes Dr. Karen Davidson, a trailblazer in airway diagnostics and a disruptor in the world of nasal health. Dr. Karen takes us through her unconventional 34-year journey,from critical care flight nurse to patented inventor and airway educator,revealing how we've misunderstood nasal function for decades.Together, they unravel the science behind nasal resistance, debunk myths about CPAP therapy, and dive into why nasal function,not volume determines breathing quality. Dr. Karen shares how she pioneered the Daphne Score and the concept of pseudo-UARS, offering a data-driven approach to understanding airflow, pressure, and airway compensation.We also explore the systemic effects of nasal resistance,from heart rate variability in athletes to sleep-disordered breathing in children misdiagnosed with ADHD. With bold insights and a refreshing dose of cynicism, Dr. Karen challenges the current medical system and encourages collaboration across specialties to improve patient care.Highlights:Dr. Karen's journey from nurse to airway innovator and educatorWhy nasal function, not just nasal breathing mattersHow nasal resistance affects posture, speech, sleep, and heart rateThe creation and science behind the Daphne Score and airway AIUnderstanding pseudo-UARS and overexpansion risks in orthodonticsCPAP intolerance and why it often fails due to undiagnosed nasal resistanceThe flawed "disease management" model in healthcareWhy sleep doesn't disorder breathing, breathing disorders sleepNasal function as a key factor in ADHD misdiagnosis and childhood airway issuesFunctional diagnostics: From facial analysis to RhinoManometryThe neurological connection between nasal resistance and tongue functionThe importance of individualized treatment based on nasal flow and pressureThe emerging International Society of Airway Function Diagnostics & TherapeuticsAbout the Guest:Dr. Karen Fields-Lever is a critical care flight nurse, airway diagnostics expert, and creator of the patented Daphne Score software used to analyze nasal resistance and flow. With over 8,000 cases of ENT experience, she brings a rare blend of clinical and industry insight to breathing science. A published author and educator, Dr. Karen has pioneered flow-based orthodontics, Maverick nasal exams, and teaches across multiple specialties, including dentistry, ENT, chiropractic, and physical therapy. She is the founder of the International Society of Airway Function Diagnostics and Therapeutics, and her mission is clear: redefine how we measure, interpret, and treat the airway.Resources MentionedWebsite | karenparkerdavidson.comFounder of |International Society of Airway Function, Diagnostics, & TherapeuticsInstagram | @_thenoseknowsBooks MentioneDAmazon Link

In this Huberman Lab Essentials episode, my guest is Dr. Matthew Johnson, PhD, a senior researcher for the Center of Excellence for Psilocybin Research and Treatment at Sheppard Pratt's Institute for Advanced Diagnostics and Therapeutics. We explore the science and therapeutic potential of psychedelic medicine, including psilocybin, MDMA and LSD. We discuss how these substances can profoundly alter perception and self-identity, providing long-lasting relief from depression, addiction and trauma when used in controlled clinical settings. We also discuss microdosing and emerging research on psychedelics' potential to support recovery from neurological injuries. Read the episode show notes at hubermanlab.com. Thank you to our sponsors AG1: https://drinkag1.com/huberman David: https://davidprotein.com/huberman BetterHelp: https://betterhelp.com/huberman Timestamps 00:00:00 Matthew Johnson; Psychedelics 00:01:44 Different Classes of Psychedelics 00:04:33 Psychedelics & Altering Models 00:06:18 Sponsor: David 00:07:33 LSD, Psylocibin & Serotonin 00:09:55 Psychedelic Clinical Trials 00:13:40 Therapy, Trust, Psychedelics 00:16:47 Letting Go & Psychedelic Experience, Self-Representation, Lasting Changes 00:22:31 Sponsors: AG1 & BetterHelp 00:25:26 MDMA, Dopamine & Serotonin; Bad Trips & Transcendental Experience 00:28:49 Dangers of Psychedelics 00:31:11 Microdosing Psychedelics, Antidepressant 00:35:27 Head Injuries, Psychedelics, Depression 00:38:29 Acknowledgements Disclaimer & Disclosures Learn more about your ad choices. Visit megaphone.fm/adchoices

Kirk Huntsman, Chairman, CEO, and Co-Founder of Vivos Therapeutics, is focused on the connection between obstructive sleep apnea and Alzheimer's disease, the challenges of diagnosing sleep apnea, and the importance of sleep testing in treating the root causes of sleep disorders. The Vivos oral appliance is a non-invasive way to address the breathing disorder OSA and resulting sleep issues. Proper nasal breathing and airway development from a young age can help prevent the onset of sleep apnea and help preserve brain health. Kirk explains, "Sleep apnea is an interesting condition that has only been actively researched for the last 60 years. It was really only identified and started showing up in the medical literature in the mid-1960s. And so we really have about a 60-year run at trying to figure out what this condition is, what it affects, what's comorbid with it, etc. We're now pushing 40 plus conditions, which are comorbid with sleep apnea, and every time we find another condition that is coexistent with sleep apnea or that is found in connection with sleep apnea, we just expand the horizon for that and we learn more about the sort of the biomechanical and the biological processes that are at work that drive the connection between these two. And you mentioned one of the main ones now that we've known about for a while, but the connection between obstructive sleep apnea in particular and Alzheimer's." "What we know is that there's a drainage system on the brain. Our brains need to get into a deep state of rest, and it's called REM sleep. And there are other parts to this. I'll keep it really high level, but the bottom line is that our brains flush. There's a sewage system that basically flushes the toxins out of our brains. It's called the glymphatic system. And the glymphatic system needs to be able to function, and in order to function, the patient has to be in a state of deep sleep. And so if sleep apnea has interrupted that sleep and caused various arousals or various interruptions to avoid a patient arriving at that, what happens is that the brain is not able to flush the toxins out of the brain, and those toxins build up." #VivosTherapeutics #SleepApnea #ObstructiveSleepApnea #OSA #SleepDisorders #CognitiveDecline #Alzheimers #OSATreatment #MedicalDevice vivos.com Download the transcript here

Kirk Huntsman, Chairman, CEO, and Co-Founder of Vivos Therapeutics, is focused on the connection between obstructive sleep apnea and Alzheimer's disease, the challenges of diagnosing sleep apnea, and the importance of sleep testing in treating the root causes of sleep disorders. The Vivos oral appliance is a non-invasive way to address the breathing disorder OSA and resulting sleep issues. Proper nasal breathing and airway development from a young age can help prevent the onset of sleep apnea and help preserve brain health. Kirk explains, "Sleep apnea is an interesting condition that has only been actively researched for the last 60 years. It was really only identified and started showing up in the medical literature in the mid-1960s. And so we really have about a 60-year run at trying to figure out what this condition is, what it affects, what's comorbid with it, etc. We're now pushing 40 plus conditions, which are comorbid with sleep apnea, and every time we find another condition that is coexistent with sleep apnea or that is found in connection with sleep apnea, we just expand the horizon for that and we learn more about the sort of the biomechanical and the biological processes that are at work that drive the connection between these two. And you mentioned one of the main ones now that we've known about for a while, but the connection between obstructive sleep apnea in particular and Alzheimer's." "What we know is that there's a drainage system on the brain. Our brains need to get into a deep state of rest, and it's called REM sleep. And there are other parts to this. I'll keep it really high level, but the bottom line is that our brains flush. There's a sewage system that basically flushes the toxins out of our brains. It's called the glymphatic system. And the glymphatic system needs to be able to function, and in order to function, the patient has to be in a state of deep sleep. And so if sleep apnea has interrupted that sleep and caused various arousals or various interruptions to avoid a patient arriving at that, what happens is that the brain is not able to flush the toxins out of the brain, and those toxins build up." #VivosTherapeutics #SleepApnea #ObstructiveSleepApnea #OSA #SleepDisorders #CognitiveDecline #Alzheimers #OSATreatment #MedicalDevice  vivos.com Listen to the podcast here  

Send us a textIn this episode of WTR Small-Cap x Healthcare Spotlight crossover episode, we are joined by Lisata Therapeutics' (NASDAQ: LSTA) CEO David Mazzo, PhD and Chief Medical Officer Kristen Buck, MD to talk about, Certepetide, the company's novel solid tumor targeting and penetration technology with tumor microenvironment modifying properties.  We also dive into the recently reported positive preliminary results from Lisata's lead program (Ascend), a Phase 2b study investigating Certepetide for metastatic pancreatic ductal adenocarcinoma (the most common and aggressive form of pancreatic cancer), Lisata's partnerships, and upcoming milestones.  

In this episode of Careers in Discovery, we're joined by Paulo Fontoura, Chief Medical Officer at Xaira Therapeutics. Paulo shares his journey from neurology and academia into big pharma and now Biotech, reflecting on what he learns along the way. He talks about Xaira's bold mission to use AI not just to speed up drug development, but to rethink how we do it entirely - overcoming human limitations in how we explore biology. We also discuss why he leaves a successful career in pharma for the high-risk world of startups, how he stays optimistic in the face of failure, and what it really takes to build a company that's aiming to change the game. A thoughtful conversation with a leader bringing deep experience - and fresh perspective - to the future of drug discovery.

We love to hear from our listeners. Send us a message. On this week's episode, Roger Cone, Ph.D., Founder and Chair of the Scientific Advisory Board at Courage Therapeutics, talks about discovering obesity-related protein receptors in the brain, how he spun his academic discoveries out into a biotech company developing new obesity drugs, the need for obesity treatments with fewer side effects than currently available GLP-1 therapies, and the value of pairing scientific leadership with a strong business partner as CEO. This episode of the Business of Biotech is brought to you by Ecolab. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Marc Shenouda, CEO and Co-Founder of Neuropeutics Inc., gives insights into targeted therapeutics for neurodegenerative disease, winning the AbbVie Biotech Innovator's Award, and earlier detection for ALS. Get full access to NPC Healthbiz Weekly at healthbiz.substack.com/subscribe

Join i3 Health for a special live webinar, Optimizing Neuroendocrine Tumor Outcomes: Closing the Gaps in Diagnosis and Care, being held on Thursday, July 17th at 12:00 pm Eastern and on Tuesday, August 5th at 3:00 pm Eastern. In this exclusive event, Dr. Aman Chauhan, Leader of the Neuroendocrine Tumor Program at the University of Miami, Sylvester Comprehensive Cancer Center, will share his expertise and latest insights in the treatment of NETs. In this interview, Dr. Chauhan shares a preview of the topics he is excited to highlight during the webinar, including the recent advances which are transforming patient care, the emerging field of theranostics, the evolving role of multidisciplinary care, and practical tips for effective team collaboration. Don't miss this opportunity to learn from one of the leading voices in NETs care. Register at the link below or scan the QR code in the video to secure your spot. We look forward to seeing you! Register Here! July 17, 2025 @ 12:00 PM ET: https://us02web.zoom.us/webinar/register/WN_2VJ0PmYISae4gAh2KxNlnQ#/registration August 5, 2025 @ 3:00 PM ET: https://us02web.zoom.us/webinar/register/WN_teUE5QgyQJ6sYaLRrkNp9g#/registration

This week on Careers in Discovery, we're joined by Tim Sparey, Executive Chair at Tay Therapeutics and Non-Executive Chair at Concr. Tim shares his journey from early days as a medicinal chemist at Merck to a career spanning business development, CEO roles, and now chairing multiple early-stage Biotech companies. He talks about the shift from operator to portfolio leader, how he evaluates new opportunities, and why capital efficiency is a critical part of Biotech success - especially in the current market. We also dive into Tay's approach to doing more with less, how Concr is applying AI to reshape precision oncology, and what Tim looks for in founding teams. Along the way, he reflects on the value of learning from setbacks, building trust with investors, and why simplicity, storytelling, and timing make all the difference.

Corcept Therapeutics, Inc v. Teva Pharmaceuticals USA, Inc.

In this powerful episode (#35) of BioTalk Unzipped, recorded live at the AAPS NBC conference in Boston, Gregory Austin engages in a deep conversation with a leading Neuroscientist, Dr. Robert Thorne, Denali Fellow at Denali Therapeutics, for an intimate and scientific deep dive into the evolving world of brain cancer treatment and CNS drug delivery. Both Gregory and Dr. Thorne share personal stories of losing family members to brain metastases, weaving in the emotional 'why' behind their professional paths.Dr. Thorne highlights the complexities of the blood-brain barrier, the heterogeneity of brain metastases, and cutting-edge delivery technologies—including focused ultrasound and molecular engineering approaches. The conversation also touches on pediatric brain tumors like diffuse midline glioma (DIPG), emerging research in lysosomal storage diseases, and the collaborative spirit driving innovation in neuroscience today.This is more than a technical discussion—it's a human story about grief, hope, and the relentless pursuit of better outcomes for patients with brain diseases.00:00 Preview & Intro01:10 Robert Thorne's Reflections on the AAPS NBC conference03:14 The Professional Biotech and Pharma League05:09 A Personal Story Shared: Family Loss to Brain Cancer07:57 My Reason for Optimism Treating Brain Cancer08:50 Why Brain Metastases Remain Hard to Treat11:10 Scientific Advances in Drug Delivery for Brain Cancer12:30 Seed and Soil Concept in Oncology15:18 Pediatric Brain Tumors: DNET, DIPG, and Beyond16:49 Looking Ahead: Hope for Future Therapies21:32 Closing GratitudeDr. Robert Thornehttps://www.linkedin.com/in/robert-g-thorne/Denali Therapeutics - https://www.denalitherapeutics.com/ Dr. Chad Briscoehttps://www.linkedin.com/in/chadbriscoe/ Celerion - https://www.celerion.com/ Gregory Austinhttps://www.linkedin.com/in/gregoryaustin1/ Celerion - https://www.celerion.com/ Key Takeaways:Personal Connection Fuels Professional Passion: Both Gregory and Dr. Thorne were driven into the life sciences field by family experiences with brain tumors.The Blood-Brain Barrier (BBB) Remains a Major Challenge: Brain metastases from cancers like melanoma, lung, and breast cancer still present difficult delivery barriers for therapies.Heterogeneity in Brain Mets: Different metastases within the same patient can have vastly different BBB permeability, requiring multifaceted delivery strategies.Emerging Drug Delivery Innovations: Focused ultrasound, engineered biologics, and Denali's own delivery platforms are all promising ways to improve CNS drug penetration.Pediatric Brain Cancers Present a Unique Set of Challenges: Diseases like diffuse midline glioma (DIPG) remain largely untreatable, but learnings from lysosomal storage disorders may translate in the...

Michael Barry, Adjunct Associate Professor, Pharmacology & Therapeutics and Clinical Director National Centre for Pharmacoeconomics, outlines how much pharmaceutical companies are paying out to healthcare professionals and organisations.

Abbas Kazimi, CEO of Nimbus Therapeutics, shares his insights about leadership in biopharma and how Nimbus is working to design and develop small molecule medicines capable of improving patients' lives.

A surgeon in burns reconstruction, Matt Klein swapped the operating room for the equally high-pressure environment of drug development. In this episode of Pathfinders in Biopharma, he sets out the vision for the company he now leads, PTC Therapeutics – a pioneer in the field of RNA therapies, now powering towards profitability with treatment candidates for a host of rare diseases.

Joining us on this episode is Tom Neyarapally, co-founder and CEO of Archetype Therapeutics, an exciting new AI-driven company in the drug discovery space. Archetype is an AI-native biotech pioneering the use of generative chemogenomics and patient clinicogenomic data to virtually screen billions of potential drug candidates each day.⁠⁠TPM E47 highlights >⁠⁠⁠⁠⁠⁠⁠⁠Episode 47 links:Archetype TherapeuticsTom Neyarapally on LinkedIn “Exploring a “Patient-First” Path in Drug Discovery”, a LinkedIn article by Tom Neyarapally, Paul McDonagh, and Rafael Rosengarten

In this episode of the RCP Medicine podcast, Professor Ailsa Hart and Dr Eathar Shakweh discuss how to approach managing Inflammatory Bowel Disease (IBD) in the acute medical setting. This is the second episode of a 2-part series, with a focus on Crohn's disease. IBD is a common condition, affecting 1 in 123 people in the UK. The 2024 State of the IBD Care in the UK report highlighted the urgent need to shorten time to diagnosis and initiate early treatment to minimise the risk of IBD-related complications. Acute and general medicine physicians have an important role to play in diagnosing and managing IBD. This podcast will equip medics at all stages of training with the necessary knowledge to approach this heterogenous and complex condition. Professor Hart is Director of IBD Research at St Mark's Hospital, London, United Kingdom and a world-leading expert in IBD. Eathar is an IBD Clinical Research Fellow at St Mark's and Imperial, with a special interest in perianal fistulising Crohn's disease. Crohn's & Colitis UK (CCUK) Websitehttps://crohnsandcolitis.org.uk/This is a valuable resource for patients and healthcare professionals alike, containing a wealth of information on IBD investigation and management.British Society of Gastroenterology (BSG) guidelines on Inflammatory Bowel Disease (IBD) - 2019Lamb, Christopher Andrew et al. “British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.” Gut vol. 68,Suppl 3 (2019): s1-s106. doi:10.1136/gutjnl-2019-318484https://pubmed.ncbi.nlm.nih.gov/31562236/For interested listeners, these are the national guidelines for IBD diagnosis and management. Please note, the new guidelines for 2025 are pending release.ECCO Guidelines on Therapeutics in Crohn's disease: Medical TreatmentTorres, Joana et al. “ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment.” Journal of Crohn's & colitis vol. 14,1 (2020): 4-22. doi:10.1093/ecco-jcc/jjz180https://pubmed.ncbi.nlm.nih.gov/38877997/ECCO Guidelines on Surgery in Crohn's disease: Surgical TreatmentAdamina, Michel et al. “ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment.” Journal of Crohn's & colitis vol. 18,10 (2024): 1556-1582. doi:10.1093/ecco-jcc/jjae089https://pubmed.ncbi.nlm.nih.gov/38878002/These are the European Crohn's and Colitis Organisation (ECCO) guidelines on therapeutics in Crohn's disease, divided into medical and surgical treatment.RCPEducation and learning | RCP CreditsMusic bensound.com

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/TRR865. CME/MOC/AAPA credit will be available until June 30, 2026.Mission Possible in Prostate Cancer: Leveraging Genomics, Modern Therapeutics, and Individualized Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/TRR865. CME/MOC/AAPA credit will be available until June 30, 2026.Mission Possible in Prostate Cancer: Leveraging Genomics, Modern Therapeutics, and Individualized Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/TRR865. CME/MOC/AAPA credit will be available until June 30, 2026.Mission Possible in Prostate Cancer: Leveraging Genomics, Modern Therapeutics, and Individualized Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/TRR865. CME/MOC/AAPA credit will be available until June 30, 2026.Mission Possible in Prostate Cancer: Leveraging Genomics, Modern Therapeutics, and Individualized Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/TRR865. CME/MOC/AAPA credit will be available until June 30, 2026.Mission Possible in Prostate Cancer: Leveraging Genomics, Modern Therapeutics, and Individualized Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

We love to hear from our listeners. Send us a message.In this episode of Cell & Gene: The Podcast, Host Erin Harris interviews Dr. Gloria Matthews, Chief Medical Officer of Aegle Therapeutics, a clinical-stage regenerative medicine company focused on developing therapies for rare and severe dermatologic and immunologic disorders. Dr. Matthews explains how Aegle is pioneering the use of extracellular vesicles (EVs) derived from mesenchymal stem cells, which offer advantages over traditional cell-based therapies. Their discussion highlights Aegle's lead product, AGLE-102 as well as the regulatory and manufacturing challenges of scaling EV-based therapies. They cover the broader therapeutic potential of EVs in areas such as graft-versus-host disease, ocular, and orthopedic disorders, and more.Subscribe to the podcast!Apple | Spotify | YouTube

From lab curiosity to commercial reality. Here's what happens when moss meets the brutal economics of bioprocessing.In Part 1, you've heard the science behind moss-based protein production. Now comes the real test: Can it survive the gauntlet of regulatory scrutiny, cost pressures, and manufacturing scale-up that crushes most biotech innovations?In Part 2 of this groundbreaking conversation, David Brühlmann and Andreas Schaaf, Managing Director and CSO of Eleva, dive into the nuts and bolts of what it actually takes to commercialize a revolutionary production platform. Andreas doesn't just theorize—he's lived through 15+ years of transforming Eleva from startup concept to clinical-stage reality, navigating every regulatory hurdle and economic challenge along the way.Three game-changing advantages that caught our attention:Process Robustness That Actually Works: While CHO cells throw tantrums over minor parameter shifts, moss maintains consistent product quality even when your bioprocess isn't behaving perfectly; a lifeline for manufacturing teams dealing with real-world variability.Economics That Make CFOs Smile: Forget expensive viral filtration steps and costly human pathogen testing. Moss's plant heritage eliminates these animal-system burdens, directly impacting your bottom line in ways that matter.Operational Simplicity: Variability in process ingredients and streamlined cell banking contribute to long-term cost and operational efficiencies that compound over time.Andreas shares hard-won insights about what it really takes to challenge entrenched bioprocessing orthodoxy, including the regulatory conversations, the economic realities, and his advice for scientists brave enough to pursue game-changing innovations.Ready to understand how disruptive biotechnology actually makes it from bench to bedside?Connect with Andreas Schaaf:LinkedIn: www.linkedin.com/in/andreas-schaaf-b3797716Website: www.elevabiologics.comNext step:Book a free consultation to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/callDevelop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at www.bruehlmann-consulting.com/call/Support the show

This week on Careers in Discovery, we're joined by Remi-Martin Laberge, Co-founder and Chief Technology Officer of Arda Therapeutics. Remi shares his journey from academic research to building companies, the lessons he learned at Unity Biotechnology, and how Arda is using single-cell sequencing and targeted antibodies to eliminate disease-driving cells in chronic conditions. We talked about the leap from scientist to founder, applying oncology tools beyond cancer, and why curiosity and risk-taking go hand in hand in Biotech.  

What if the future of "impossible" protein therapeutics is hiding in your backyard?For decades, CHO cells have ruled the biotech kingdom as the undisputed champions of complex protein production. But here's the uncomfortable truth: countless breakthrough therapies are gathering dust on laboratory shelves—not because the science failed, but because traditional hosts can't produce them.Enter moss. Yes, moss. That humble green organism clinging to rocks and trees might just be the biotech industry's best-kept secret.In this eye-opening episode, David Brühlmann sits down with Andreas Schaaf, Managing Director and CSO of Eleva, who's spent over 20 years turning the "impossible" into reality. Andreas didn't just stumble upon moss; he co-developed Eleva's revolutionary moss-based platform from wild concept to commercial-scale game-changer, propelling the company into clinical trials.Here are three reasons why this episode is worth listening to:Moss as a Game Changer: More than a plant, moss is a higher eukaryote with mammalian-like protein production, including post-translational modifications and human-compatible glycosylation.Overcoming Bioprocessing Barriers: CHO cells are the industry gold standard, especially for monoclonal antibodies. But what about the therapeutic proteins that CHO can't handle? Many promising candidates end up shelved—not because the science isn't sound, but because existing production platforms hit their limits.Bioprocessing, Simplified: Moss grows in standard bioreactors using familiar workflows—just with a whole organism instead of suspended cells.Curious about how plant-based systems could solve your protein production challenges? Dive into this episode to discover how moss could revolutionize your approach to challenging proteins; and let us know about your own production hurdles.Connect with Andreas Schaaf:LinkedIn: www.linkedin.com/in/andreas-schaaf-b3797716Website: www.elevabiologics.comNext step:Book a free consultation to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/callDevelop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at www.bruehlmann-consulting.com/call/Support the show

Je leest het goed. De rijkste man van de wereld heeft miljarden nodig. Geld dat 'ie gebruikt om zijn AI-imperium uit te bouwen. Het moet dé concurrent worden van OpenAI. Een bedrijf dat dan weer écht in oorlog ligt met Microsoft.We hebben het er deze aflevering over. Dan hebben we het ook over die echte oorlog. Die tussen Israël en Iran. In Iran smeken ze president Trump om een wapenstilstand in te lassen, maar daar heeft hij geen trek in. Waardoor de onzekerheid op de beurs (voor jou) nog langer aanhoudt.We ontdekten trouwens dat het ondanks die oorlog prima beleggen is in Tel Aviv. Nou ja prima. Fantastisch. Waarom dat is, je raadt het al: daarvoor moet je toch echt luisteren.Hoor je ook meer over een miljardenovername van Eli Lilly en de handelsdeal die Trump heeft gesloten met de EU. Of was het nu met het Verenigd Koninkrijk? See omnystudio.com/listener for privacy information.

Send us a textEnlivex Therapeutics CEO Oren Hershkovitz, PhD joins us on another WTR Small-Cap x Biotech Spotlight crossover episode to talk about how the company's cell therapy, Allocetra, reprograms macrophages to treat inflammatory diseases. We dive into the recent Phase 1 data in knee osteoarthritis and what to expect from the randomized Phase 2 readout later this year, as well as the market opportunity. Listen to learn more about Enlivex Therapeutics and its off-the-shelf cell therapy platform. 

Dr. Kilian Kelly, Chief Executive Officer and Managing Director of Cynata Therapeutics, has taken on the challenge of manufacturing stem cell therapies consistently and at scale in order to drive the advancements necessary for the next generation of regenerative medicine. Cynata is employing a novel approach that utilizes a single source of pluripotent stem cells (iPSCs) and mesenchymal cell ancestors (MCAs) to generate mesenchymal stem cells (MSCs). Lead programs are targeting graft-versus-host disease, osteoarthritis, and diabetic wounds, where clinical trials have shown great promise to treat these and other diseases. Kilian explains, "We're a stem cell regenerative medicine company, and what we're trying to do is to change the way that we can manufacture stem cell therapies in a consistent and scalable way. I'm sure many of your listeners have heard about stem cell therapies of various types. The particular type of cells that we're working on are called mesenchymal stem cells or MSCs. They've shown lots of promise for lots of different purposes, but a real challenge has been making these cells consistently, especially when you try to do that at a large scale. We have a unique novel manufacturing platform, which helps us to address that major challenge." "The way that these cells were historically produced and indeed still are produced in most cases is by harvesting cells from, for example, somebody donating bone marrow or adipose tissue, also known as fat. And those approaches have certainly allowed a lot of early-stage clinical trials to be performed, which showed lots of really exciting results. But often what happens is that when you move to a larger scale using such a process, and you try to make much larger quantities of cells, perhaps using many different donors, you start to see a lot of inconsistency. There are a few reasons for this. When you have inconsistency with a product, it's inevitable that you're going to get inconsistent results." "If you have inconsistent results in a clinical trial, it becomes a bit of a lottery, and sometimes you can have very disappointing results that are hard to explain. So we think that's been a really big issue that has caused a lot of problems in the field. And aside from the impact on clinical trial results, we also need to think about the future when these products are available and on the market, and how you can actually, in practical terms, produce enough of these products. So, in a nutshell, I think that is probably the major challenge that the field has faced."  #CynataTherapeutics #StemCellTherapy #RegenerativeMedicine #iPSCs #MSCs #MCAs Cynata.com Download the transcript here  

Dr. Kilian Kelly, Chief Executive Officer and Managing Director of Cynata Therapeutics, has taken on the challenge of manufacturing stem cell therapies consistently and at scale in order to drive the advancements necessary for the next generation of regenerative medicine. Cynata is employing a novel approach that utilizes a single source of pluripotent stem cells (iPSCs) and mesenchymal cell ancestors (MCAs) to generate mesenchymal stem cells (MSCs). Lead programs are targeting graft-versus-host disease, osteoarthritis, and diabetic wounds, where clinical trials have shown great promise to treat these and other diseases. Kilian explains, "We're a stem cell regenerative medicine company, and what we're trying to do is to change the way that we can manufacture stem cell therapies in a consistent and scalable way. I'm sure many of your listeners have heard about stem cell therapies of various types. The particular type of cells that we're working on are called mesenchymal stem cells or MSCs. They've shown lots of promise for lots of different purposes, but a real challenge has been making these cells consistently, especially when you try to do that at a large scale. We have a unique novel manufacturing platform, which helps us to address that major challenge." "The way that these cells were historically produced and indeed still are produced in most cases is by harvesting cells from, for example, somebody donating bone marrow or adipose tissue, also known as fat. And those approaches have certainly allowed a lot of early-stage clinical trials to be performed, which showed lots of really exciting results. But often what happens is that when you move to a larger scale using such a process, and you try to make much larger quantities of cells, perhaps using many different donors, you start to see a lot of inconsistency. There are a few reasons for this. When you have inconsistency with a product, it's inevitable that you're going to get inconsistent results." "If you have inconsistent results in a clinical trial, it becomes a bit of a lottery, and sometimes you can have very disappointing results that are hard to explain. So we think that's been a really big issue that has caused a lot of problems in the field. And aside from the impact on clinical trial results, we also need to think about the future when these products are available and on the market, and how you can actually, in practical terms, produce enough of these products. So, in a nutshell, I think that is probably the major challenge that the field has faced."  #CynataTherapeutics #StemCellTherapy #RegenerativeMedicine #iPSCs #MSCs #MCAs Cynata.com Listen to the podcast here  

Michael Ringel is the Chief Operating Officer of Life Biosciences, a biotechnology company pioneering cellular rejuvenation therapies to reverse and prevent multiple diseases of aging. Michael became COO of Life just a few months ago, but he's been advising the company since 2018. Prior to this year, he was managing director and senior partner at Boston Consulting Group (BCG), where over a 25-year career he focused on R&D and innovation initiatives across the private sector and government. He earned his PhD in biology at Imperial College London and a JD from Harvard Law, and has become an active and highly respected member of the global longevity biotech community.In this episode, Chris and Michael explore Life Biosciences' groundbreaking approach to partial epigenetic reprogramming - the "holy grail" technology that could transform how we age at cellular, tissue, and organism levels. They discuss how this approach taps into the same biology that makes babies young, Life's lead therapeutic candidate ER-100 for eye diseases, and the "pipeline in a pill" concept at the core of the geroscience hypothesis: the idea that enable single interventions based on longevity science could treat multiple age-related diseases simultaneously.The Finer Details:The biology behind partial epigenetic reprogramming and how it differs from full reprogramming to pluripotencyWhy Michael considers partial reprogramming the "holy grail" of longevity interventionsLife Biosciences' lead candidate ER-100 for glaucoma and NAION (non-arteritic anterior ischemic optic neuropathy)The innovative inducible system that allows the therapy to be turned on and off with doxycyclineWhy the eye represents an ideal starting point for reprogramming therapiesThe "pipeline in a pill" concept and geroscience hypothesis - how single interventions could treat multiple age-related diseasesParallels between the emerging longevity field and the massive GLP-1 drug market that many pharma companies missedThe role of philanthropic investment in advancing fundamental longevity researchEvolutionary theories of aging and why aging should be easily manipulableTimeline expectations for moving from single disease treatments to whole-body rejuvenationLinksLife Biosciences company websiteMichael Ringel's ARDD talk

In this episode of FYI – For Your Innovation, Brett Winton and ARK analyst Nemo Despot sit down with Generate Biomedicines CEO Mike Nally and CFO Jason Silvers to explore how generative AI is transforming the discovery and development of protein-based therapeutics. Founded in 2018 by Flagship Pioneering, Generate Biomedicines is building a “self-driving lab” that combines machine learning, cryo-electron microscopy (cryo-EM), and high-throughput wet lab automation to dramatically accelerate drug development. The conversation dives into how Generate is reimagining protein therapeutics — going beyond trial-and-error methods to a data-first, design-driven model for creating novel medicines. The team discusses the company's proprietary approach to integrating structural biology with functional data, the economic implications of reducing time-to-market from 13 years to under 9, and how their platform could unlock treatments for diseases that have been historically undruggable. They also touch on strategic partnerships, scalability, and how AI is shifting the biotech business model from artisanal science to an industrialized, data-driven enterprise.Key Points From This Episode:00:01:30 Why Generate Biomedicines is rethinking protein drug discovery from first principles00:04:40 How their structure-first approach differs from peers like AbSci and Recursion00:07:04 Using cryo-EM to build proprietary protein interaction datasets00:10:57 Traditional drug discovery is random, expensive, and inefficient — here's how Generate is changing that00:16:58 From concept to clinic in 18–24 months: Accelerating timelines through AI00:20:47 Going beyond efficiency: Unlocking access to undruggable biology00:24:48 Turning cryo-EM into a high-throughput data engine for model training00:31:20 The long-term vision: Patient-specific protein therapeutics00:40:00 Why scalability gives Generate an edge over traditional biotech00:47:52 The future of biotech as a research & development (R&D) sharing economy00:54:19 Adapting fast: Keeping pace with generative AI advances across the stack01:00:16 The KPI (key performance indicator) for platform success: Rate of improvement

What if targeting a single cellular pathway could slow aging and boost immunity? Dr. Joan Mannick, a leading voice in aging science, reveals how mTOR inhibitors may be the future of longevity therapeutics. From her early inspiration to groundbreaking clinical trials, Dr. Mannick explores the role of mTOR in aging, immune response, and antiviral immunity. Learn how selective mTOR inhibition could extend healthspan without compromising muscle mass, improve vaccine response in older adults, and unlock new possibilities in clinical longevity. Learn more about Dr. Joan Mannick: https://www.linkedin.com/in/joan-mannick-8089a614/ - Download Dr. Buck Joffrey's FREE ebook, Living Longer for Busy People: https://ru01tne2.pages.infusionsoft.net/?affiliate=0 Book a FREE longevity coaching consultation with Dr. Buck Joffrey: https://coaching.longevityroadmap.com/

Methylene blue is widely marketed over the counter to the general public as well as to the natural health, health freedom, and freedom communities, often on the internet. It is flooding America.   Some sellers are touting methylene blue as a “miracle” tonic that improves “cognitive function”1 and boosts energy to previously unimagined heights. Some have given live demonstrations on TV and podcasts demonstrating how the oral form hyperactivates some people within 35 minutes of the first dose — a typical stimulant drug rush — which is actually a danger signal for potentially activating them into a dangerous manic episode during future exposures or even more deadly outcomes.   Read the full article here: Methylene Blue is highly neurotoxic to your brain and mind   In reality, methylene blue is a lethal neurotoxin, a poison to the brain. It has the same basic chemical composition and harmful clinical effects as the oldest and most neurotoxic “antidepressants,” the monoamine oxidase inhibitors (MAOIs). It also has similarities to the neurotoxic phenothiazine “antipsychotic” drugs, including the original Thorazine (chlorpromazine), but methylene blue is more stimulating or activating.   Methylene blue is not a miraculous new discovery. It is the opposite. Created in 1876 in a lab — it is the oldest manmade chemical to be used in medicine. But in well over a century, methylene blue has never been FDA-approved for psychiatric purposes. Later, its chemical structure was modified in labs for creating many of the earliest, most neurotoxic psychiatric drugs.   Methylene blue suppresses or destroys forms of the enzyme monoamine oxidase that are used by the brain for controlling or modulating four different powerful neurotransmitters — serotonin, dopamine, norepinephrine, and epinephrine. In short, by crushing monoamine oxidase, methylene blue causes overstimulation of four of the brain's major neurotransmitters, all of which profoundly impact the mind.   After the FDA was created in 1906, methylene blue was grandfathered into the market by the agency as an obscure antidote for methemoglobinemia, but it must be emphasized that the FDA has never tested the safety of methylene blue for any purpose. Furthermore, the FDA, based on its adverse reporting system and scientific reports, has published serious warnings about potentially lethal adverse reactions from methylene blue, especially when combined with numerous other drugs.2   The first MAOIs used as depressants were derived from methylene blue, and they turned out to be so toxic that the first two were quickly taken off the market by the FDA. One caused lethal liver disease, and the other caused hypertensive crises. Methylene blue is known to impair liver function tests and to cause hypertensive crises. Early on, all MAOIs were removed for a while from the international list of approved drugs. Please go to this endnote in my report  for a list of historical and scientific studies about the extraordinary history and the nature of methylene blue and the other MAOIs.3   Psychiatry and the psychopharmaceutical complex are so driven to impose neurotoxins upon our brains ⎯ some MAOI antidepressants remain on the market today. FDA Full Prescribing Information for the existing MAOI antidepressants, readily available online,4 provides quick access to the kinds of adverse effects caused by methylene blue. These FDA documents also provide lists of the foods and of some of the many, many drugs you cannot take with MAOIs, like methylene blue, without risking death from serotonin syndrome or a hypertensive crisis.   Meanwhile, all of America is being made a market for the original mother of them all, methylene blue, without requiring a prescription, with bizarrely distorted claims, and with unlimited supplies handed out as easily as a new caffeinated soda.   All of the three approved MAOIs, as well as methylene blue, carry repeated warnings at the FDA and in the scientific community about causing the two potentially crippling and lethal outcomes, serotonin syndrome and malignant hypertension (see below). These potentially lethal outcomes, as with all MAOIs, become much more serious and higher risk when methylene blue is taken with certain foods such as cheese and bananas, or literally with so many other drugs that it is impossible to memorize them or to keep track of them.   Here is one version of a short summary of the long list of dangerous interactions between MAOIs, including methylene blue, and other drugs and foods, taken from Goodman and Gilman's The Pharmacological Basis of Therapeutics (2018, p. 274):   Monoamine Oxidase Inhibitors   Serotonin syndrome is the most serious drug interaction for the MAOIs (see Adverse Effects). The most common cause of serotonin syndrome in patients taking MAOIs is the accidental coadministration of a SHT reuptake-inhibiting antidepressant or tryptophan. Other serious drug interactions include those with meperidine and tramadol. MAOIs also interact with sympathomimetics such as pseudoephedrine, phenylephrine, oxymetazoline, phenylpropanolamine, and amphetamine; these are commonly found in cold and allergy medication and diet aids and should be avoided by patients taking MAOIs. Likewise, patients on MAOIs must avoid foods containing high levels of tyramine: soy products, dried meats and sausages, dried fruits, home-brewed and tap beers, red wine, pickled or fermented foods, and aged cheeses.   I am presenting this detailed summary in the hope of gaining the immediate attention of people and businesses who are promoting methylene blue and anyone who is unfortunately taking it. Please share this summary or the entire document as widely as possible and with proper attribution.   An extensive article follows, detailing my professional experience in the arena of psychopharmacology. It includes a lengthy scientific analysis with more than two dozen endnotes containing an even greater number of scientific citations.   Read the full article here: Methylene Blue is highly neurotoxic to your brain and mind   End Notes   1 All stimulants from caffeine to Ritalin (methylphenidate) and on to methamphetamine and cocaine, and including MAOIs, can produce subjective feelings of improved concentration or memory, and some short-term studies show a brief improvement. This is caused by obsessive-compulsive mental focusing and is driven by a narrowing of general awareness and judgment.  No FDA-approved stimulants, for example, have been proven to help cognition or academic performance, and all harm the brain long-term.  Here is a study that is negligent in its claims and its lack of warnings about methylene blue that may have encouraged the current epidemic use: https://psychiatryonline.org/doi/full/10.1176/appi.pn.2016.pp8a5 I have researched these issues in multiple scientific papers and books, including Brain-Disabling Treatments in Psychiatry: Drugs, Electroshock, and the Psychopharmaceutical Complex, second edition (2008).  For an easily accessible, comprehensive look at stimulant drug effects, also see my free resource center on children and stimulant medications: https://breggin.com/Childrens-Resources-Center   2 Drug Safety Communication: Serious CNS reactions possible when methylene blue is given to patients taking certain psychiatric medications | FDA and FDA Drug Safety Communication: Updated information about the drug interaction between methylene blue and Drug Safety Podcasts > FDA Drug Safety Podcast for Healthcare Professionals: Updated information about the drug interaction between methylene blue and serotonergic psychiatric medications (methylthioninium chloride) and serotonergic psychiatric medications | FDA and much more comprehensive coverage of methylene blue adverse effects with special warnings for professionals can be found at Methylene Blue Monograph for Professionals – Drugs.com   3 Half_a_century_of_antidepressant_drugs_-20151101-21548-vmvosk-libre.pdf. Also see Methylene Blue: The Long and Winding Road From Stain to Brain: Part 2 – PubMed and Methylene Blue in the Treatment of Neuropsychiatric Disorders – PubMed; and Iproniazid | Antidepressant, Monoamine Oxidase Inhibitor & Mental Health | Britannica; Methylene Blue: The Long and Winding Road From Stain to Brain: Part 2 – PubMed; Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today – PubMed. These cover the fascinating history of MAOIs and Methylene Blue.    4 The currently approved MAOI antidepressants are phenelzine (Nardil), tranylcypromine (Parnate), selegiline (Eldpryl, Emsam, Zelapar)), and isocarboxazid (Marplan).     ______   Learn more about Dr. Peter Breggin's work: https://breggin.com/   See more from Dr. Breggin's long history of being a reformer in psychiatry: https://breggin.com/Psychiatry-as-an-Instrument-of-Social-and-Political-Control   Psychiatric Drug Withdrawal, the how-to manual @ https://breggin.com/a-guide-for-prescribers-therapists-patients-and-their-families/   Get a copy of Dr. Breggin's latest book: WHO ARE THE “THEY” - THESE GLOBAL PREDATORS? WHAT ARE THEIR MOTIVES AND THEIR PLANS FOR US? HOW CAN WE DEFEND AGAINST THEM? Covid-19 and the Global Predators: We are the Prey Get a copy: https://www.wearetheprey.com/   “No other book so comprehensively covers the details of COVID-19 criminal conduct as well as its origins in a network of global predators seeking wealth and power at the expense of human freedom and prosperity, under cover of false public health policies.”   ~ Robert F Kennedy, Jr Author of #1 bestseller The Real Anthony Fauci and Founder, Chairman and Chief Legal Counsel for Children's Health Defense.